论文部分内容阅读
目的 探讨大剂量胸腺肽合并干扰素治疗慢性丙型肝炎的疗效和安全性。方法 治疗组以胸腺肽 16 0mg加10 %葡萄糖 2 5 0ml静脉滴注 ,每周 3次。α干扰素 3MIU肌注 ,每周 3次。对照组 ,单用α干扰素 3MIU肌注 ,每周 3次 ,疗程均为 6个月。结果 大剂量胸腺肽合并干扰素治疗组HCVRNA阴转率 6 6 6 7% ,ALT复常率 76 19% ,对照组HCVRNA阴转率33 33% ,ALT复常率 76 19% ,对照组HCVRNA阴转率 33 33% ,ALT复常率 5 2 38% ,两组经统计学处理有显著差异 ( P <0 0 5 )。结论 大剂量胸腺肽合并干扰素治疗慢性丙型肝炎疗效好 ,较安全
Objective To investigate the efficacy and safety of high-dose thymosin combined with interferon in the treatment of chronic hepatitis C Methods The treatment group thymosin 160mg plus 10% glucose 250ml intravenous infusion, three times a week. Interferon alpha 3MIU intramuscular injection, 3 times a week. The control group, intramuscular injection of α interferon 3MIU alone, 3 times a week, treatment were 6 months. Results The HCV RNA negative conversion rate was 66.767% and ALT normalization rate was 76.19% in the high-dose thymosin combined with interferon treatment group. The negative control rate of HCV RNA was 33.33% and the abnormal ALT rate was 76.19% 33 33% rate of change, ALT normalization rate of 5 2 38%, the two groups were statistically significant differences (P <0 05). Conclusion High-dose thymosin combined with interferon in the treatment of chronic hepatitis C is effective and safe